Royal Bank of Canada
KZR

Royal Bank of Canada’s Kezar Life Sciences KZR Stock Holding History

Royal Bank of Canada’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
322
+210
+188% +$1.37K ﹤0.01% 6712
2025
Q4 		$1K Buy
+112
New +$653 ﹤0.01% 7007
2024
Q3 		– Sell
-346
Closed -$2K – 7154
2024
Q2 		$2K Buy
346
+183
+112% +$1.39K ﹤0.01% 6736
2024
Q1 		$1K Sell
163
-2,079
-93% -$18.9K ﹤0.01% 6810
2023
Q4 		$21K Buy
2,242
+1,044
+87% +$9.18K ﹤0.01% 6294
2023
Q3 		$14K Buy
1,198
+452
+61% +$8.01K ﹤0.01% 6310
2023
Q2 		$18K Buy
746
+447
+149% +$11.6K ﹤0.01% 6266
2023
Q1 		$9K Sell
299
-498
-62% -$28.8K ﹤0.01% 6367
2022
Q4 		$56K Buy
797
+719
+922% +$53.3K ﹤0.01% 5809
2022
Q3 		$7K Buy
78
+50
+179% +$4.86K ﹤0.01% 6595
2022
Q2 		$2K Sell
28
-205
-88% -$18.1K ﹤0.01% 6963
2022
Q1 		$39K Sell
233
-377
-62% -$54.1K ﹤0.01% 6251
2021
Q4 		$102K Buy
610
+215
+54% +$24.3K ﹤0.01% 5918
2021
Q3 		$34K Buy
395
+161
+69% +$10.7K ﹤0.01% 6384
2021
Q2 		$13K Sell
234
-15
-6% -$852 ﹤0.01% 6773
2021
Q1 		$15K Buy
249
+102
+69% +$5.96K ﹤0.01% 6599
2020
Q4 		$8K Buy
+147
New +$8.18K ﹤0.01% 6480
2020
Q3 		– Sell
-5
Closed – – 6790
2020
Q2 		$0 Sell
5
-10
-67% -$505 ﹤0.01% 6767
2020
Q1 		$1K Sell
15
-103
-87% -$4.19K ﹤0.01% 6452
2019
Q4 		$5K Buy
+118
New +$3.63K ﹤0.01% 6357
2018
Q4 		– Sell
-22
Closed -$5K – 6940
2018
Q3 		$5K Buy
+22
New +$3.84K ﹤0.01% 6263

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Royal Bank of Canada's KZR Position: Q1 2026 in Review

Royal Bank of Canada increased its Kezar Life Sciences (KZR) stake by 188% in Q1 2026, buying an estimated $1.37K and bringing the position to 322 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6712.

Royal Bank of Canada first reported a position in KZR in Q3 2018 and has held it in 21 quarters since. The position peaked at $102K in Q4 2021. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Royal Bank of Canada held 322 shares of Kezar Life Sciences worth $2K as of Q1 2026.
  • Royal Bank of Canada bought 210 Kezar Life Sciences shares in Q1 2026, an estimated $1.37K.
  • Kezar Life Sciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6712 holding.
  • Royal Bank of Canada first reported a position in Kezar Life Sciences in Q3 2018 and has held it in 21 quarters since.
  • Royal Bank of Canada's Kezar Life Sciences position peaked at $102K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.